
Sign up to save your podcasts
Or
Jonathan Violin, CEO of Crescent Biopharma and Venture Partner at Fairmount, speaks with Venrock partner Nimish Shah about how the company is keeping a frenetic and exciting pace to generate a new class of drugs while preparing to launch on the public markets later this year.
4.8
6262 ratings
Jonathan Violin, CEO of Crescent Biopharma and Venture Partner at Fairmount, speaks with Venrock partner Nimish Shah about how the company is keeping a frenetic and exciting pace to generate a new class of drugs while preparing to launch on the public markets later this year.
1,271 Listeners
2,189 Listeners
1,017 Listeners
991 Listeners
1,782 Listeners
2,298 Listeners
3,978 Listeners
123 Listeners
317 Listeners
5,920 Listeners
1,539 Listeners
31 Listeners
146 Listeners
10 Listeners
44 Listeners